Purple Biotech Reports Second Quarter 2026 Financial Results
Purple Biotech reported Q2 2026 net income of $0.4 million, reversing a net loss of $1.1 million in the prior-year period, primarily due to a non-cash gain from the revaluation of outstanding warrants. The company released new preclinical data for IM1240, demonstrating an 8-fold longer half-life and 16-fold greater systemic exposure compared to non-capped variants, supporting a planned first-in-human study in 2027.
Key figures
- Cash runway
- mid-2027
- Cash position
- 6100000
- Operating loss
- 1300000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.